Navigated laser and aflibercept versus aflibercept monotherapy in treatment-naïve branch retinal vein occlusion: A 12-month randomized trial.

Katrine Hartmund FrederiksenJesper Pindbo VestergaardFrederik Nørregaard PedersenAnna Stage Vergmann Torben Lykke SørensenCaroline Schmidt LaugesenRyo KawasakiTunde Peto Jakob Grauslund

Published in: Acta ophthalmologica (2022)

In treatment-naïve BRVO patients, addition of navigated central laser to aflibercept did not lower treatment burden or affect functional or anatomical outcomes. A low number of intravitreal injections were needed for successful outcome in both treatment arms.

Keyphrases

randomized controlled trial
combination therapy
ejection fraction
end stage renal disease
type diabetes
metabolic syndrome
risk factors
diabetic retinopathy
mass spectrometry
endothelial cells
age related macular degeneration
vascular endothelial growth factor
patient reported outcomes